Ovarian Cancer Research Outlines the Role of ADCs, PARP Inhibitors, and Surgery
Hope Cottrill, MD, highlights key points that were presented at a State of the Science Summit meeting, including the role of bevacizumab plus PARP inhibitors in ovarian cancer management, how to manage adverse events associated with antibody-drug conjugates, and ongoing research in ovarian cancer risk reduction.
United States Triciai Fredricks David Schweer Laurena Baldwin Baptist Health Medical Group Gynecologic Oncology Baptist Health Medical Group In Lexington
Source: onclive.com